Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 7/20 | 0.67 |
| ▸ | KAT2A | Q92830 | 2/20 | 0.61 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 2/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679134 | 1.00 | CASP3 (0.67) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL11130291 | 0.87 | CASP3 (0.63) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL29679182 | 0.83 | CASP3 (0.63) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL3142380 | 0.83 | CASP3 (0.63) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL7630656 | 0.83 | CASP3 (0.68) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL3143600 | 0.80 | CASP3 (1.00) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL29678965 | 0.80 | CASP3 (1.00) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL15423262 | 0.80 | FAAH (0.69) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL11278746 | 0.80 | CASP3 (0.74) | CASP3KAT2AKAT2BFAAHMGLL | |
| SCHEMBL17948304 | 0.80 | CASP3 (0.72) | CASP3KAT2AKAT2BFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022202958-A1 | NON-AQUEOUS SECONDARY BATTERY POLYMER COMPOSITION AND NON-AQUEOUS SECONDARY BATTERY | 旭化成株式会社 | 2022-09-29 | — | — | WO | disclosed |
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2021-11-11 | — | — | US | disclosed |
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | THE UNIVERSITY OF TOLEDO (US) | 2021-07-06 | — | — | US | disclosed |
| CN-113036132-A | Polymer composition for nonaqueous secondary battery and nonaqueous secondary battery | 旭化成株式会社 | 2021-06-25 | — | — | CN | disclosed |
| CN-113036133-A | Polymer composition for nonaqueous secondary battery, and nonaqueous secondary battery | 旭化成株式会社 | 2021-06-25 | — | — | CN | disclosed |
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2020-04-09 | — | — | US | disclosed |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2019-05-30 | — | — | US | disclosed |
| US-20050013794-A1 | Composition and use | ARCH UK BIOCIDES LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
| US-20050014670-A1 | Composition and use | ARCH UK BIOCIDES | 2005-01-20 | — | — | US | disclosed |
| US-20050009971-A1 | Composition and use | ARCH UK BIOCIDES | 2005-01-13 | — | — | US | disclosed |
| US-20050008534-A1 | Composition and use | ARCH UK BIOCIDES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100666-A1 | ANTIMICROBIAL COMPOSITION CONTAINING A POLYMERIC BIGUADINE AND A COPOLYMER AND USE THEREOF | ARCH UK BIOCIDES LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100663-A1 | ANTIMICROBIAL COMPOPSITION COMPRISING A POLYMERIC BIGUANIDE AND A COPOLYMER AND THEIR USE THEREOF | ARCH UK BIOCIDES LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100664-A1 | COMPOSITION COMPRISING AN ACIDIC COPOLYMER AND AN ANTIMICROBIAL AGENT AND USE THEREOF | ARCH UK BIOCIDES LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100665-A1 | ANTIMICROBIAL COMPOSITION COMPRISING A POLYMERIC BIGUANIDE AND A COPOLYMER AND USE THEREOF | ARCH UK BIOCIDES LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| US-6005032-A | PROTECTION OF THERMOP;ASTIC RESINS WITH FUNGICIDES | ZENECA LIMITED (GB) | 1999-12-21 | — | — | US | disclosed |
| EP-0804078-B1 | COMPOSITION AND USE | ZENECA LTD (GB) | 1999-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008534-A1 | Composition and use | TST, TH, ARG1 | CASP3 1852/4885KAT2A 2072/4885KAT2B 2182/4885 |
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | CASP3 3617/4885KAT2A 3922/4885KAT2B 3223/4885 |
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | CASP3 3617/4885KAT2A 3922/4885KAT2B 3223/4885 |
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | AIFM1, HSPE1, COX15 | CASP3 10/4885KAT2A 2502/4885KAT2B 2305/4885 |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | AIFM1, HSPE1, COX15 | CASP3 10/4885KAT2A 2502/4885KAT2B 2305/4885 |
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | CASP3 3617/4885KAT2A 3922/4885KAT2B 3223/4885 |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CASP3 919/4885KAT2A 109/4885KAT2B 248/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CASP3 919/4885KAT2A 109/4885KAT2B 248/4885 |
| US-20050013794-A1 | Composition and use | H1-0, ARG1, C5 | CASP3 3347/4885KAT2A 2758/4885KAT2B 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.